Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors.
J. C. Dawson, A. Munro, K. Macleod, M. Muir, P. Timpson, R. Williams, M. C. Frame, V. Brunton, N. O. Carragher
This study profiles the effects of the SRC inhibitor AZD0424 in combination with MEK inhibitors, showing reduced compensatory activation and enhanced anti-tumor effects in colorectal cancer models.
bioRxiv · Aug 27, 2021 · PreprintCancer Biology